Relationship of Serum Pentraxin-3 with Peripheral Arterial Disease

Analysis of PTX3 values with other parameters (age, systolic and diastolic blood pressure, heart rate, respiratory rate, temperature, and SpO2) revealed no significant correlation with any of the other parameters.Conclusion: Our findings indicate that PTX3 levels cannot be used as a marker in patients with the chronic process of PAD.

📌 3 Key Takeaways

🎯

Objective & Hypothesis:Aim: Atherosclerosis is a chronic inflammatory process associated with peripheral artery disease (PAD).

📊

Key Findings & Data:The purpose was to determine the value of PTX3 in the diagnosis of PAD.

💡

Conclusion & Impact:Analysis of PTX3 values with other parameters (age, systolic and diastolic blood pressure, heart rate, respiratory rate, temperature, and SpO2) revealed no significant correlation with any of the other parameters.Conclusion: Our findings indicate that PTX3 levels cannot be used as a marker in patients with the chronic process of PAD.

🔬Design:Research Article

📍Scope:Comprehensive Sample

⚙️Variables:Domain Parameters

Abstract

Aim: Atherosclerosis is a chronic inflammatory process associated with peripheral artery disease (PAD). The aim of this study was to investigate the role of pentraxin (PTX) as an inflammatory marker in the pathogenesis of PAD.Materials and Methods: This cross-sectional clinical study was performed at the tertiary university hospital emergency department and cardiovascular sur-gery departments in Turkey. The purpose was to determine the value of PTX3 in the diagnosis of PAD. This study was performed on 43 symptomatic patients aged >18 years and diagnosed with PAD.Results: Median PTX3 value was 1.027 (25–75th percentile: 0.395–2.902) in the control group and 0.585 (25–75th percentiles: 0.406–5.467) in the PAD group (p=0.913). A comparison of PTX3 with ankle brachial index (ABI) values revealed a weak and non-significant correlation (rho: 0.016, p=0.886). Analysis of PTX3 values with other parameters (age, systolic and diastolic blood pressure, heart rate, respiratory rate, temperature, and SpO2) revealed no significant correlation with any of the other parameters.Conclusion: Our findings indicate that PTX3 levels cannot be used as a marker in patients with the chronic process of PAD.

🔖

Cite This Article

KATİPOĞLU, B., AYGÜN, A., MENTEŞE, A., GÜNDÜZ, A., KORKUT, S., DEMİR, S., ALTUN, G., MENTEŞE, Ü., ÖREM, A., TATLI, Ö. (2022). Relationship of Serum Pentraxin-3 with Peripheral Arterial Disease. Eurasian Journal of Emergency Medicine, Cilt: 17 - Sayı: 4, 187–192. https://ajindex.com/articles/508065

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (2)

Cecilia A. Gutierrez. Peripheral Arterial Disease. In: Paulman PM, Paulman AA, Harrison Taylor JD, editors.Taylor’s Manual of Family Medicine. Philadelphia: Lippincott Williams &Wilkins; 2008. p.339-43.
Van der Wal AC, Becker AE, Das PK. Medial thinning and atherosclerosis--evidence for involvement of a local inflammatory effect. Atherosclerosis. 1993; 103: 55-64. [CrossRef] Fazzini F, Peri G, Doni A, Dell’Antonio G, Dal Cin E, Bozzolo E, et al. PTX3 in small-vessel vasculitides: an independent indicator of disease activity produced at sites of inflammation. Arthritis Rheum. 2001; 44: 2841-50. [CrossRef] Carbayo JA, Divisón JA, Escribano J, López-Abril J, de Coca EL, Artigao LM, et al. Using ankle-brachial index to detect peripheral arterial disease: prevalence and associated risk factors in a random population sample. Nutr Metab Cardiovasc Dis. 2007; 17: 41-9. [CrossRef] Menke A, Muntner P, Wildman RP, Dreisbach AW, Raggi P. Relation of borderline peripheral arterial disease to cardiovascular disease risk. Am J Cardiol. 2006; 98: 1226-30. [CrossRef] Karabay O, Karacelik M, Yilik L, Tekin N, Iriz AB, Kumdereli S, et al. Ischemic peripheral arterial disease: A screening survey. Turk J Thoracic Cardiovasc Surg. 2012; 20: 450-7. [CrossRef] Ambrosetti M. Timely diagnosis of lower extremity peripheral arterial disease: one of the many expected actions by the cardiologist. Int J Cardiol. 2014; 175: 217. [CrossRef] Akman L, Erbas O, Terek MC, Aktug H, Taskiran D, Askar N. The long pentraxin-3 is a useful marker for diagnosis of ovarian torsion: An experimental rat model. J Obstet Gynaecol. 2016; 36: 399-402. [CrossRef] Tatlı O, Keha Kurt N, Karaca Y, Sahin A, Aygun A, Sahin E, et al. The diagnostic value of serum pentraxin 3 levels in pulmonarycontusion. Am J Emerg Med. 2017; 35: 425-8. [CrossRef] Tomandlova M, Jarkovsky J, Tomandl J, Kubkova L, Kala P, Littnerova S, et al. Prognostic value of pentraxin-3 level in patients with STEMI and its relationship with heart failure and markers of oxidative stress. Dis Markers. 2015; 2015: 159051. [CrossRef] Zhou Y, Ni Z, Zhang J, Zhang W, Wu Q, Shen G, et al. Plasma pentraxin 3 may be a better marker of peripheral artery disease in hemodialysis patients than C-reactive protein. Vasc Med. 2013; 18: 85-91. [CrossRef] Morishita T, Uzui H, Nakano A, Mitsuke Y, Geshi T, Ueda T, et al. Number of endothelial progenitor cells in peripheral artery disease as a marker of severity and association with pentraxin-3, malondialdehyde-mo